Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-10-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于不向下修正 “微芯转债” 转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('微芯转债'). It details the bond issuance, the conditions triggering price adjustment, and the board's resolution not to adjust the conversion price despite the triggering event. The document is relatively short (2023 characters) and focuses on a specific corporate action related to convertible bonds, not a full financial report or earnings release. It is a regulatory announcement about capital structure and bond terms, fitting the category of Capital/Financing Update (CAP).
2024-10-18 Chinese
自愿披露关于CS231295片临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (CS231295) by the National Medical Products Administration. It details the drug's basic information, clinical trial phase, and regulatory acceptance notice. The document is an official announcement about regulatory acceptance of a clinical trial application, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed financial analysis. It is not a report publication announcement since it contains substantive information about the clinical trial acceptance. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-10-17 Chinese
关于 “微芯转债” 预计满足转股价格修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the expected triggering of convertible bond conversion price adjustment conditions. It details the issuance and listing of convertible bonds, the terms of conversion price adjustments, the potential triggering events, and the company's obligations to disclose further information. The document is regulatory in nature, providing an update on convertible bond terms and potential price adjustments, but it does not contain financial statements, earnings data, or detailed financial analysis. It is not a full financial report, earnings release, or management discussion. It is also not a notice of dividend, share issue, or merger activity. The document is a formal regulatory announcement about convertible bond terms and potential adjustments, fitting best under Regulatory Filings (RNS). The document length is short (2047 characters), and it is a standalone announcement rather than a report or presentation.
2024-10-11 Chinese
关于可转债转股结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding convertible bond (可转债) conversion results and related share capital changes for Shenzhen Microchip Biotechnology Co., Ltd. It provides details on the amount of convertible bonds converted into shares during a specific quarter and cumulatively, as well as the remaining unconverted bonds. It also includes information about the bond issuance, listing, and conversion price adjustments. The document is relatively short (1808 characters) and focuses on the update of convertible bond conversion and share capital changes rather than a full financial report or detailed financial statements. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond conversions and share capital changes.
2024-10-08 Chinese
自愿披露关于公司入选国家级第六批专精特新“小巨人”企业的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. about the company being selected as a national-level 'Specialized and New Little Giant' enterprise. It contains no financial data, no mention of financial results, no regulatory filings or certifications, and no meeting or voting information. It is a general corporate announcement about a recognition or award, not a report or financial filing. The document length is short (845 characters), and it is an announcement of a status update rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-09-09 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司2024年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024年半年度持续督导跟踪报告" (2024 Half-Year Continuous Supervision Tracking Report) issued by the sponsor institution 国投证券股份有限公司 for 深圳微芯生物科技股份有限公司. It contains detailed information about the continuous supervision work, risk factors, financial data for the first half of 2024, R&D progress, use of raised funds, and shareholding status of key personnel. The document covers a half-year period and includes substantive financial data and analysis, such as revenue, net profit, cash flow, and R&D expenses. It is not merely an announcement or a certification but a comprehensive report on the company's half-year performance and supervision status. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.